AGENDA

Powerful sessions in various formats (Presentations, panels, and round tables) from expert speakers hitting groundbreaking territory and discussing what matters most.

Learn More

SPEAKERS

Distinguished industry leaders who come prepared to actively engage and share the latest insights.

Learn More

TESTIMONIALS

The EPMRC was one of the most informative, thought-provoking and insightful conferences that I have attended for several years. I recommend EPMRC as a must attend to all those in market research and decision support roles across Europe.

 

Merck / MSD

See More

SUBSCRIBE FOR UPDATES

CONFERENCE DAY 1
20 October, Thursday, 2016
CONFERENCE DAY 2
21 October, Friday, 2016

Registration & Networking Breakfast in Exhibition Hall

Chairpersons’ Opening Remarks

Keynote: Newness. Predicting the Future with the Internet of People

Miguel Jimenez, Head of Strategy, Fast Forward

Change is the new normal.

It doesn’t matter how fast your strategy advances, there’s always a gap that makes your competitors move faster. Digital acceleration and massive demographics define an era where every business is in the business of interaction and experiences. You are not a pharma manufacturer, you are a pharma services company. Learn about how to use people as newness sensors to identify opportunities that will lead your company into a better competitive landscape. We cannot predict the future, but if we observe every detail shaping the present, we can invent it and we can lead it.

Keynote: Johnson & Johnson Innovation Model, Partnering in Europe

Networking & Refreshments in Exhibition Hall

Keynote Panel: Reaction/Response to Keynote Presentations

(panelists are Advisory Board Members)
Katrin Hoffmann, Global Commercial Insights Lead, Gastrointestinal/Internal Medicine Business Unit, Shire
Guy Murray, Director, Market Research & Analytics, MSD
Lottie Pollak, Head of Global Market Research, GlaxoSmithKline
Susanne West, Head of European Market Intelligence, Teva Pharmaceuticals Europe
Xander Wiewel, Global Customer Insights Leader, Elanco

Networking Luncheon

PARTICIPANTS MAY CHOOSE 1 OF 2 CONCURRENT TRACKS

TRACK A

Awareness Alone is Not Enough!

Barbara Walser, Director, Market Research, Dynamics and Competitive Intelligence, AgNovos Healthcare GmbH

High awareness does not ensure high acceptance/sales of a product.

Prevent the pitfalls associated with one-dimensional ATU-trackers: clarify the relevance of messaging to physicians.

TRACK B

Presentation: iAdBoard®: An Online Solution for Traditional Market Research

Amalia De Luca, Ph.D., Consultant, Lifescience Dynamics Limited

• Pros and cons of online research and bulletin board solutions

• What do respondents think of the online experience?
• The client’s prospective
• A case study with both physicians and payers

PARTICIPANTS MAY CHOOSE 1 OF 2 CONCURRENT TRACKS

TRACK A

Merge of Clinical Evidence and Market Research for Valuable Insights

Frank Schiepe, Director Global Market Insights & Business Analytics, Vifor Fresenius Medical Care Renal Pharma

TRACK B

The Only Way is Mobile: Drug Forecasting in the Age of Personalized Medicine

Robert Dossin, European Client Solutions Director, SKIM

With the odds stacked against a new product in a complex, competitive market, one pharma client needed insights that traditional market research methods just couldn’t touch.

Which patients? What type? How many? What the brand team didn’t expect was an approach that captured prescribing intent with such precision that it turned round conventional thinking and elevated a ‘simple forecast’ to a robust, compelling evidence base for a winning strategic direction. Powering fresh momentum, confident decisions, more impactful customer engagement and better informed physicians, the ‘in-the-moment’ clarity of mobile forecasting proved the albeit unanticipated driving force that ensured a successful launch.

Networking & Refreshments in Exhibition Hall

PARTICIPANTS MAY CHOOSE 1 OF 2 CONCURRENT TRACKS

TRACK A

How Do We Get Past ‘Normalisation’ When Researching Chronic Diseases?

Nicola Cowland, CEO, Cello Health Insight

• What approaches can be used to portray the reality of patients’ clinical burden? Who do you need to engage with and how?

• How can you reveal normalisation to the patient so they ‘see’ it and communicate their experience of a disease or treatment more accurately?
• How can you address normalisation to in a way such that patients get and stay on track with treatment?
• How can you know that normalisation is taking place if patients themselves can’t see it?

Normalisation leads to under-reporting by patients of the clinical burden of disease and is one of the biggest challenges we face in customer insight research. It leads to disconnection in patient-HCP interactions, undermines compliance and persistence and makes it hard for patients to identify their unmet needs. Getting to understand patients better from early stage by unravelling normalisation and its consequences is invaluable in the push for improvement in treatment, devices and new formulations.

TRACK B

What Drives Patients to Choose Your Information Website - The Added Value of Implicit Methods

Alisa Missling, Research Consultant User Experience, eye square GmbH

The presented study focuses on patient’s needs and expectations towards an information website.

Four pharma-hosted diabetes websites in the German-speaking area were explored in a representative online survey with 90 patients suffering from Diabetes type I or II. In addition to explicit survey data, implicit, physiological measures were employed in order to reveal what patients cannot express or talk about a. A number of best practices are derived that help to create information websites that really fit users’ needs and therefore foster the market success of your brand.

PARTICIPANTS MAY CHOOSE 1 OF 2 CONCURRENT TRACKS

TRACK A

Challenges of How to Maximize, Leverage the Data All Around You

Dennis Engelke, Director, Business Analysis & Insight, Jazz Pharmaceuticals
Xavier Franco, Associate Director - Global Market Research, Shire (invited)
Katrin Hoffmann, Global Commercial Insights Lead, Gastrointestinal/Internal Medicine Business Unit, Shire

TRACK B

Maximizing Market Research Throughout an Organization

Christina Chan, Senior BAI Manager – Oncology, RE and AfME, Pfizer (invited)
Jack Jing, Global Business Development Manager, Seacross Pharmaceuticals
Marco Koch, Senior Director, Central Market Research Group, Merz Pharmaceuticals

Evening Socializing & Networking Reception in Exhibition Hall

Registration & Networking Breakfast in Exhibition Hall

Deep-Dive Round Table Discussions

(Explore hot topics in a fast-paced, interactive and informal environment. Interested in more than one round table topic? Round tables will be held in two consecutive, back to back 45 minute sessions.)
ROUND TABLE 1
How to Best Execute Market Research When Confronted with Very Small Universe Sizes
Gernot Schoeggl, Customer Insights, EMEA, Elanco
ROUND TABLE 2
Patient Centricity – How to Track in the Real World
Frank Schiepe, Director Global Market Insights & Business Analytics, Vifor Fresenius Medical Care Renal Pharma
ROUND TABLE 3
Embedding Patient Centricity in the Corporate Culture – How Market Research Can Contribute
Marco Koch, Senior Director, Central Market Research Group, Merz Pharmaceuticals
ROUND TABLE 4
The Upside Potential of a Drug Related to an Underserved Population

Networking & Refreshments in Exhibition Hall

PARTICIPANTS MAY CHOOSE 1 OF 2 CONCURRENT TRACKS

TRACK A

A Structured Approach to Set Up a Market Intelligence Organisation

Bernold Beckenbauer, Head of Healthcare Market Intelligence, Linde

- Presentation of a structured approach to setup a new market intelligence organization

– Presentation of process & essentials to setup a market intelligence organization
– Key areas to focus on initially
– Value of using an established framework

TRACK B

Identifying Emerging Treatment Algorithms Using Process Tracing

Doug Wilson, Ph.D., Senior Vice President, A+A

Process tracing is a method for investigating how physicians and other healthcare providers make diagnosis and treatment decisions.

Originally developed for consumer market research on choice processes conducted in the 1970’s, process tracing investigates the steps physicians take to acquire information about their patients, as well as their ultimate diagnosis or treatment decisions. This presentation shows how process tracing methods can be used in qualitative and quantitative market research to identify the treatment algorithms that physicians and other healthcare providers actually use in their practices.

PARTICIPANTS MAY CHOOSE 1 OF 2 CONCURRENT TRACKS

TRACK A

Data Protection

Guy Murray, Director, Market Research & Analytics, MSD

TRACK B

Lights, Camera, Insight: The Developing Role Of Filmmaking In Market Research

Steve Martino, Co-Managing Partner, M Health
John Surie, Customer Insight Director, M Health

In a world of YouTube, Netflix, and Instagram, market researchers would do well to harness the arts of filmmaking and storytelling.

Increasingly, these are the coin of the realm when it comes to informing, engaging and enlightening audiences of all kinds. This talk looks at how the power of motion picture is being applied today to the capture and dissemination of market research insights.

Networking Luncheon

Announcement of Raffle Prize Winners

From Basic Science to Spin-off Companies in the Pharmaceutical Space

Dr. Peter H. Seeberger, Professor, Freie Universität Berlin, Institute of Chemistry and Biochemistry

Funding of the basic sciences results in major payoffs to society by means of tech transfer as well as the creation of companies.

Using automated oligosaccharide synthesis and continuous chemistry as examples, this presentation will show how fundamental advances in science have resulted in novel vaccines and efficient processes for active pharmaceutical ingredient production. The breakthroughs have been patented and resulted in spin-off companies in Germany that garnered significant funding.

How CI Can Complement MR

Rafaat Rahmani, BBA, MBA, Founder & President, Lifescience Dynamics Limited

• Summary of the differences between MR and CI

• How can CI add to a MR project: when a hybrid CI + MR project could be a good choice
• Designing a hybrid project: either concurrent or sequential research
• Survey results from those that work with both CI and MR

Summary & Key Takeaways

(panelists are Advisory Board Members)
Katrin Hoffmann, Global Commercial Insights Lead, Gastrointestinal/Internal Medicine Business Unit, Shire
Guy Murray, Director, Market Research & Analytics, MSD
Lottie Pollak, Head of Global Market Research, GlaxoSmithKline
Susanne West, Head of European Market Intelligence, Teva Pharmaceuticals Europe
Xander Wiewel, Global Customer Insights Leader, Elanco

Conference Concludes